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A bs tr ac t
Background
An effective vaccine for malaria is urgently needed. Naturally acquired immunity to 
malaria develops slowly, and induction of protection in humans can be achieved 
artificially by the inoculation of radiation-attenuated sporozoites by means of more 
than 1000 infective mosquito bites.
Methods
We exposed 15 healthy volunteers — with 10 assigned to a vaccine group and 5 as-
signed to a control group — to bites of mosquitoes once a month for 3 months 
while they were receiving a prophylactic regimen of chloroquine. The vaccine group 
was exposed to mosquitoes that were infected with Plasmodium falciparum, and the 
control group was exposed to mosquitoes that were not infected with the malaria 
parasite. One month after the discontinuation of chloroquine, protection was as-
sessed by homologous challenge with five mosquitoes infected with P. falciparum. 
We assessed humoral and cellular responses before vaccination and before the chal-
lenge to investigate correlates of protection.
Results
All 10 subjects in the vaccine group were protected against a malaria challenge with 
the infected mosquitoes. In contrast, patent parasitemia (i.e., parasites found in the 
blood on microscopical examination) developed in all five control subjects. Adverse 
events were mainly reported by vaccinees after the first immunization and by con-
trol subjects after the challenge; no serious adverse events occurred. In this model, 
we identified the induction of parasite-specific pluripotent effector memory T cells 
producing interferon-γ, tumor necrosis factor α, and interleukin-2 as a promising 
immunologic marker of protection.
Conclusions
Protection against a homologous malaria challenge can be induced by the inocula-
tion of intact sporozoites. (ClinicalTrials.gov number, NCT00442377.)
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Malaria is responsible for a sig-nificant burden of morbidity and mor-tality in the developing world, and an 
effective vaccine against this disease is urgently 
needed.1 Despite decades of research, a licensed 
vaccine is still not available, largely because im-
munity to Plasmodium falciparum malaria is consid-
ered difficult to acquire, whether through natu-
ral exposure or artificially through vaccination. 
A further critical factor is our incomplete under-
standing of precisely what constitutes protective 
antimalarial immunity in humans.
The possibility of vaccinating humans against 
P. falciparum malaria was raised originally by the 
success of the radiation-attenuated sporozoite 
model developed several decades ago.2,3 Irradia-
tion of infectious mosquitoes disrupts the gene 
expression of sporozoites, which remain capable 
of hepatocyte invasion but are no longer capable 
of complete liver-stage maturation or progression 
to the pathogenic blood stage.4 Infection of hu-
man volunteers with irradiated sporozoites thus 
exposes them to liver-stage antigens and generates 
pre-erythrocytic immunity. However, the require-
ment of a minimum of 1000 bites by irradiated 
mosquitoes during five or more immunization ses-
sions in order to successfully induce sterile immu-
nity in humans5 precludes this method for routine 
immunization.
A subunit vaccine can be developed on the basis 
of antigens expressed by pre-erythrocytic, intra-
erythrocytic, or sexual stages of the parasite. Un-
fortunately, results of many such subunit vaccines 
in humans have been disappointing. To date, only 
one candidate vaccine, which is based on the cir-
cumsporozoite protein and known as RTS,S, has 
progressed to phase 3 field trials. The protection 
induced by this vaccine is encouraging, but the 
ultimate success of this approach remains to be 
determined.6-9
In rodent models, sterile protection against 
malaria can be achieved by the inoculation of in-
tact sporozoites while treating the animals con-
comitantly with chloroquine,10 a drug that kills 
parasites in the asexual blood stage but not in 
the pre-erythrocytic stage.11 The efficacy of this 
treatment is significantly higher than that of the 
radiation-attenuated sporozoite model.12 We there-
fore designed a proof-of-concept study in volun-
teers who had not been previously exposed to 
malaria to investigate whether protection can be 
induced by this approach in humans and to ex-
plore the immune responses elicited.
Me thods
Study Subjects
We recruited 15 healthy volunteers between the 
ages of 18 and 45 years who had no history of 
malaria or of living in an area in which malaria 
is endemic in the 6 months before study entry. 
Only one volunteer had ever been in an endemic 
area, several years earlier. All volunteers under-
went routine physical examination and hemato-
logic and biochemical screening at the Clinical 
Research Center at Radboud University Nijmegen 
Medical Centre. The results of serologic analysis 
for the human immunodeficiency virus (HIV), 
hepatitis B and C, and asexual P. falciparum para-
sites were negative in all subjects. 
Study Oversight
All subjects provided written informed consent. 
The trial was approved by the institutional review 
board at the Radboud University Nijmegen Medi-
cal Centre. The study sponsor, the Dioraphte Foun-
dation, was not involved in the design of the 
study, in the gathering or analysis of the data, or 
in the writing of the manuscript. All authors vouch 
for the accuracy and completeness of the data. 
Study Design 
We randomly assigned the subjects in a double-
blind fashion to two study groups: 10 to a vaccine 
group and 5 to a control group (Fig. 1). The mean 
(±SD) age of the subjects was 22.0±1.5 years in 
the vaccine group and 24.0±1.4 years in the con-
trol group; seven subjects in the vaccine group were 
women, as were four subjects in the control group.
Chloroquine was provided to all subjects in a 
standard prophylactic regimen of a loading dose 
of 300 mg on each of the first 2 days and then 
300 mg once a week, starting on day 7, for a total 
duration of 13 weeks. While receiving chloro-
quine, subjects in the vaccine group were exposed 
on three occasions at monthly intervals to bites 
of 12 to 15 mosquitoes that had been infected 
with P. falciparum, for a total exposure of bites from 
36 to 45 infected mosquitoes per subject. Control 
subjects received bites from an equal number of 
uninfected mosquitoes on the same occasions.
Anopheles stephensi mosquitoes were reared ac-
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cording to standard procedures at our insectary. 
Infected mosquitoes were obtained by feeding on 
gametocytes of NF54, a chloroquine-sensitive 
strain of P. falciparum, as described previously.13 
NF54 is genetically homogeneous but has not 
been formally cloned. Only the technicians who 
prepared the mosquitoes were aware of their in-
fectivity status, and these staff members had no 
clinical involvement with the subjects or the in-
vestigators. Blood-engorged mosquitoes were dis-
sected to confirm the presence of sporozoites. If 
necessary, feeding sessions were repeated until 
precisely the predefined number of infected 
mosquitoes had fed. However, a single feeding 
session was sufficient in 49 of 60 instances of 
immunization or challenge, whereas a second ses-
sion was required in just 10 instances and a third 
session in only 1 instance.
On days 6 to 10 after each immunization by 
mosquito exposure, all subjects were followed on 
an outpatient basis, and blood was drawn for stan-
dard whole-blood counts and daily peripheral-
blood smears. Any signs and symptoms were re-
corded by the attending physician as follows: mild 
events (easily tolerated), moderate events (inter-
feres with normal activity), or severe events (pre-
vents normal activity).
Eight weeks after the last immunization dose 
and 4 weeks after the discontinuation of chloro-
quine prophylaxis, all 15 subjects were challenged 
by exposure to the bites of five mosquitoes that 
were infected with the homologous NF54 strain 
of P. falciparum. This period was considered to be 
sufficient for chloroquine levels to drop below 
those that might be inhibitory to parasite multi-
plication.14 All subjects were checked twice daily 
on an outpatient basis from day 5 to day 21 for 
symptoms and signs of malaria, and hemato-
logic tests and peripheral-blood smears were 
performed.
If results of peripheral-blood testing were posi-
tive, subjects were treated with a standard curative 
combination regimen of 80 mg of artemether and 
480 mg of lumefantrine, followed by five identical 
doses at 8, 24, 36, 48, and 60 hours. The subjects 
were then followed closely for 3 days. Complete 
cure was confirmed on the basis of peripheral-
blood smears. All subjects who continued to have 
negative results on the peripheral-blood smear 
from the day of infection until day 21 after the 
challenge were presumptively treated with arte-
mether–lumefantrine.
Hematologic and biochemical measures were 
determined in routine fashion at the hospital’s 
central clinical laboratory. The use of nucleic acid 
sequence–based amplification and real-time poly-
merase-chain-reaction (PCR) assays to determine 
the densities of P. falciparum parasites have been 
described previously.15,16 Chloroquine levels were 
measured by liquid chromatography.17,18 Minimum 
therapeutic concentrations for plasma chloroquine 
levels maintained by the laboratory were 30 μg 
per liter.14
Immunologic Analysis
Venous whole blood was collected in Vacutainer 
cell-preparation tubes (CPT, Becton Dickinson)  be-
fore the first immunization and again before the 
malaria challenge. Plasma was collected and stored 
at −70°C. Peripheral-blood mononuclear cells were 
isolated by density gradient centrifugation, frozen 
in fetal-calf serum containing 10% dimethyl-
1
6/30/09
AUTHOR PLEASE NOTE:
Figure has been redrawn and type has been reset
Please check carefully
Author
Fig #
Title
ME
DE
Artist
Issue date
COLOR FIGURE
Draft 3
Sauerwein
TV
              7/30/09
Baden
Malaria
Start chloroquine prophylaxis
Vaccine group
(N=10)
Day
I-1
Day
C-1
Control group
(N=5)
Enrollment
(N=15)
Screening
(N=28 volunteers)
Double-blind
randomization
Challenge by
infected mosquito bite
Clinical follow-up;
treatment if positive
results on blood testing
Stop chloroquine prophylaxis
Discharge from Study
In
fe
ct
ed
 m
os
qu
ito
 b
ite
s
Im
m
un
iz
at
io
n 
Ph
as
e
   
 D
ay
s
Im
m
un
ol
og
ic
 a
ss
es
sm
en
t
C
ha
lle
ng
e 
Ph
as
e
U
ni
nf
ec
te
d 
m
os
qu
ito
 b
ite
s
–7
0
7
35
63
90
118
140
154
Figure 1. Study Design and Enrollment.
Immunologic assessment was performed 1 day before the first immuniza-
tion (day I-1) and 1 day before challenge infection (day C-1). A final chal-
lenge with infectious mosquito bites was performed 28 days after the dis-
continuation of chloroquine prophylaxis.
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sulfoxide, and stored in liquid nitrogen. Antibody 
titers were assessed by enzyme-linked immuno-
sorbent assay (ELISA) and immunofluorescence 
assay, according to standard protocols.19-21 Cellu-
lar responses to cryopreserved asexual parasites 
were assessed by 24-hour in vitro peripheral-blood–
stimulation assays,22 followed by intracellular cy-
tokine staining with the use of a Fix and Perm Kit 
(Caltag Laboratories) and flow cytometry. A more 
detailed description of these immunologic assays 
is provided in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org.
Statistical Analysis
We performed flow cytometric analysis using Cell-
Quest software, and all analyses were performed 
with the use of SPSS software. Differences in re-
sponses among subjects at various time points 
and between subjects in the vaccine group and 
those in the control group were analyzed by non-
parametric measures (Wilcoxon and Mann–Whit-
ney tests, respectively). A two-sided P value of less 
than 0.05 was considered to indicate statistical 
significance.
R esult s
Study Subjects
All 15 subjects completed the immunization phase 
of the study. All subjects received chloroquine pro-
phylaxis and subsequently underwent a malaria 
challenge (Fig. 1).
No parasites were seen in the peripheral-blood 
smears of any of the 10 subjects in the vaccine 
group after each of the three immunization ses-
sions during chloroquine prophylaxis. However, 
after the first immunization, a brief submicro-
scopic parasitemic episode was detected in all 
vaccinees (Fig. 2A). This finding was not unex-
pected, since chloroquine has no effect against 
either sporozoites, liver-stage parasites, or the 
early ring forms of the first generation of blood-
stage parasites that are caused by merozoites re-
leased from mature hepatic schizonts.11 After each 
of the subsequent two immunizations, a progres-
sively reduced incidence and burden of submicro-
scopic parasitemia was seen.
In line with these findings, all vaccinees re-
ported solicited or unsolicited symptoms that were 
recorded as adverse events at least once during 
the immunization phase. With the exclusion of 
local itching after the mosquito bites, adverse 
events were most commonly reported after the 
first immunization (in 9 of 10 subjects), with 
headache being the most frequent symptom (re-
ported by 7 subjects) (Table 1). Only a few adverse 
events were reported in the vaccine group subse-
quently (in two subjects after the third immuni-
zation). Severe adverse events were reported by 
22p3
100,000
P.
 fa
lc
ip
ar
um
 (n
o.
/m
l)
P.
 fa
lc
ip
ar
um
 (n
o.
/m
l)
1,000
10,000
100
10
100,000
1,000
10,000
100
10
B Challenge Phase
A Immunization Phase
0 2 4 6 8 10 12
Days after Infection
MPS
NASBA
−1 6 7 8 9 10
Immunization
Phase I
0/10
10/10
−1 6 7 8 9 10
Immunization
Phase III
0/10
3/10
−1 6 7 8 9 10
Immunization
Phase II
0/10
6/10
AUTHOR:
FIGURE:
JOB:
4-C
H/T
RETAKE
SIZE
ICM
CASE
EMail Line
H/T
Combo
Revised
AUTHOR, PLEASE NOTE: 
Figure has been redrawn and type has been reset.
Please check carefully.
REG F
Enon
1st
2nd
3rd
Roestenberg
2 of 3
07-30-09
ARTIST: ts
36105 ISSUE:
Control
Vaccine
Figure 2. Parasitemia in the Vaccine Group and the Control Group.
Panel A shows the mean number of Plasmodium falciparum parasites per 
milliliter, as measured by nucleic acid sequence–based amplification 
(NASBA), after each of three immunizations on days before infection and 
during expected blood-stage parasitemia (days 6 to 10) in the vaccine 
group. The numbers of subjects who had positive results on peripheral-
blood smears for malarial parasites (MPS) and NASBA are shown below 
the graph. Panel B shows the mean number of P. falciparum parasites in  
5 subjects in the control group and 10 subjects in the vaccine group, as 
determined by real-time polymerase-chain-reaction assay before treatment 
with artemether–lumefantrine. The I bars denote standard errors.
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Table 1. Adverse Events after the First, Second, and Third Exposures to Immunizing Mosquito Bites and after Challenge with Infectious 
Mosquito Bites.* 
Adverse Event Vaccine Group (N = 10) Control Group (N = 5)
After Immunization
After 
Challenge After Immunization
After 
Challenge
Exposure I Exposure II Exposure III Exposure I Exposure II Exposure III
Abdominal pain — no.
Mild 2
Moderate 
Severe 
Fatigue — no.
Mild 1 1 7 1 2
Moderate 2 1 1 2
Severe 1
Fever — no.
Mild 2
Moderate 1
Severe 2 5
Headache — no.
Mild 4 7 2 3 2
Moderate 2 1 1 1 1 3
Severe 1 1
Loss of appetite — no.
Mild 1
Moderate 
Severe 
Malaise — no.
Mild 1 1 1
Moderate 2 1
Severe 1 1 5
Myalgia — no.
Mild 1 2 3
Moderate 2 1 4
Severe 1
Nausea — no.
Mild 3 1 1 1 1
Moderate 1 1 1 1
Severe 1
Vomiting — no. 
Mild 1
Moderate 1
Severe 
Total — no. (%)†
Mild 4 (40) 1 (10) 8 (80) 1 (20) 3 (60)
Moderate 3 (30) 1 (10) 1 (20) 2 (40) 1 (20)
Severe 2 (20) 1 (10) 1 (20) 5 (100)
* Subjects could have more than one adverse event, and reports of events could have been either solicited or unsolicited. Only adverse events 
that were possibly or probably related to the study are listed.
† The highest-grade event is listed per subject per infection.
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three vaccinees: two had a fever above 39°C after 
the first immunization, and one reported severe 
malaise after the last immunization.
After challenge with the homologous NF54 
strain of P. falciparum, asexual blood-stage para-
sites were detected in peripheral-blood smears of 
all five control subjects between days 7 and 11 
after exposure (mean prepatent period, 9.2 days). 
Real-time PCR analyses revealed the expected 
cyclical multiplication of blood-stage parasites 
(Fig. 2B). The clinical course and kinetics of para-
site multiplication were similar to those in previ-
ous studies involving subjects who had not been 
exposed to malaria,23,24 with all control subjects 
reporting severe events, in particular fever above 
39°C and malaise (Table 1). In contrast, there was 
no evidence of blood-stage parasites in any of the 
vaccinees at any time during the post-challenge 
follow-up period until day 21, either by repeated 
microscopy of peripheral-blood smears or by real-
time PCR analyses (Fig. 2B). Interestingly, in the 
week after the malaria challenge, nine vaccinees 
reported mild-to-moderate events. No serious ad-
verse events occurred during any part of the trial, 
and all 15 subjects completed follow-up according 
to protocol.
Mean peak plasma levels of chloroquine and 
desethylchloroquine were 76 μg per liter (range, 
58 to 104) and 13 μg per liter (range, 5 to 33), re-
spectively, 24 hours after administration; levels 
did not differ significantly between vaccinees and 
control subjects. The day before the malaria chal-
lenge, mean plasma levels of chloroquine and 
desethylchloroquine had dropped to 8 μg per liter 
(range, <5 to 14) and less than 5 μg per liter, re-
spectively, which were deemed to be below the 
minimum therapeutic concentrations in vivo.14 
Furthermore, blood-stage parasite multiplication 
kinetics in the control subjects were identical to 
those in previous studies,24 which suggested that 
any residual chloroquine levels had no measurable 
parasiticidal effect.
After immunization, antibody responses to 
both sporozoites and blood-stage parasites de-
veloped in vaccinees but not in control subjects, 
as shown by ELISA (Table 2) and immunofluo-
rescence assay (Fig. 1 in the Supplementary Ap-
pendix). Seroconversion to the circumsporozoite 
protein, an immunodominant sporozoite-stage and 
liver-stage antigen, occurred in eight vaccinees. In 
contrast, seroconversion to crude asexual-stage 
antigen occurred in only three vacinees. Antibod-
ies to two predominantly asexual antigens, apical 
membrane antigen 1 (AMA-1) and glutamate-rich 
protein (GLURP), both of which are leading vac-
cine candidates, were undetectable. These data are 
consistent with the relatively low-dose exposure 
to asexual blood-stage antigens in the vaccinees. 
Cellular immune responses were assessed by 
counting cytokine-producing cells in peripheral-
blood specimens from the subjects, with the use 
of intracellular cytokine staining and flow cytom-
etry after 24 hours of in vitro stimulation with 
erythrocytes infected with the homologous strain 
of P. falciparum or with uninfected erythrocytes 
(Fig. 3, and Fig. 2 and 3 in the Supplementary 
Appendix). Whereas cellular responses to unin-
fected erythrocytes did not differ in any experi-
Table 2. Antibody Reactivity.*
Test Day I-1 Day C-1
Vaccine Group (N = 10) Control Group (N = 5) Vaccine Group (N = 10) Control Group (N = 5)
No. of 
Subjects
Median Antibody 
Titer
No. of 
Subjects
Median Antibody 
Titer
No. of 
Subjects
Median Antibody 
Titer
No. of 
Subjects
Median Antibody 
Titer
AU AU AU AU
CSP 0 <12 0 <12 8 33 (21–210) 0 <12
AMA-1 ND ND 0 <5.8 0 <5.8
GLURP ND ND 0 <42 0 <42
Asexual blood- stage 
antigen
0 <0.6 0 <0.6 3 1.7 (1.5–2.0) 0 <0.6
* Data are for subjects who had a detectable response. Numbers in parentheses are ranges. All analyses were performed with the use of an 
enzyme-linked immunosorbent assay. Plasma was collected from all subjects before immunization (day I-1) and before the malaria challenge 
(day C-1). A plasma pool obtained from 100 Tanzanian adults living in an area in which malaria was endemic was used as a reference posi-
tive control, set at 100 arbitrary units (AU). Thresholds for circumsporozoite protein (CSP), apical membrane antigen 1 (AMA-1), glutamate-
rich protein (GLURP), and asexual blood-stage positivity were 12, 5.8, 42, and 0.6 AU, respectively. ND denotes not done.
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ment from responses to culture medium alone, 
stimulation with infected erythrocytes elicited 
small percentages of lymphocytes producing 
interferon-γ or TNF-α, but not interleukin-2, in 
the two groups before immunization (see day I-1 
in Figure 2 in the Supplementary Appendix).
Although there was no significant difference 
in the overall proportion of cells producing indi-
vidual cytokines (interferon-γ or TNF-α) in either 
group after immunization (day C-1), a significant 
increase was observed in the proportion of cells 
producing multiple cytokines in response to in-
fected erythrocytes in vaccinees, as compared with 
baseline: P = 0.03 for the within-group compari-
son for interferon-γ and interleukin-2; P = 0.046 
for TNF-α and interleukin-2; and P = 0.03 for 
interferon-γ, TNF-α, and interleukin-2 (Fig. 3A, 3B, 
and 3C). The importance of these pluripotent 
lymphocytes in acquired immune protection is 
suggested by their higher cytokine content and 
may reflect better effector function (Fig. 3D, 3E, 
and 3F). The major contributors to this increase 
in pluripotent lymphocytes with a response to in-
fected erythrocytes were CD3+CD45RO+ memory-
like T cells (P=0.02 for the comparison with day 
I-1) (Fig. 3G, and Fig. 3 in the Supplementary Ap-
pendix). CD4+CD8− cells showed a particularly 
marked response (P = 0.005 for the comparison 
with day I-1) (Fig. 3H). Most noticeably, these new 
pluripotent lymphocytes were predominantly of 
the effector memory CD62L−CD45RO+ pheno-
type (P = 0.005 for the comparison with day I-1), 
although there was also a small but significant 
increase in the numbers of responding central 
memory CD62L+CD45RO+ cells in vaccinees 
(P = 0.02 for the comparison with day I-1) (Fig. 3I).
Discussion
Our study shows that the inoculation of intact 
sporozoites induces more effective protection 
against a homologous challenge with P. falciparum 
malaria than does irradiation-attenuated sporo-
zoite immunization. In the endemic situation, how-
ever, nonsterile semi-immunity is acquired only 
after years of repeated natural exposure. We be-
lieve that the improved efficiency of our approach 
was due to a critical balance of exposure to pre-
erythrocytic and intraerythrocytic antigens. In 
contrast to irradiated sporozoites that arrest ear-
ly during liver-stage development,4 intact sporo-
zoites under chloroquine cover mature fully and 
develop into a first generation of blood-stage 
parasites,11 thus presenting to the host’s immune 
system a broader array of pre-erythrocytic antigens, 
as well as erythrocytic-stage antigens (albeit at 
relatively low dose). 
The contribution of intraerythrocytic antigens 
to the development of protective immunity is sug-
gested by Pombo et al.,25 who reported that re-
peated intravenous injection of ultra-low densities 
of blood-stage parasites, followed by drug cure 
with atovaquone–proguanil, induced protection in 
human volunteers against a similarly low-dose 
blood-stage challenge. However, caution needs to 
be exercised when interpreting the latter results, 
since residual concentrations of antimalarial drugs 
may partially or even fully have accounted for the 
observed protection.26
Figure 3 (facing page). In Vitro Pluripotent Cytokine  
Responses to Plasmodium falciparum Parasites  
on Flow Cytometry.
The proportion of lymphocytes that produced inter-
feron-γ (IFN-γ) and interleukin-2 (Panel A), tumor ne-
crosis factor α (TNF-α) and interleukin-2 (Panel B), or 
IFN-γ, TNF-α, and interleukin-2 (Panel C) after in vitro 
stimulation with erythrocytes infected with the homol-
ogous strain of P. falciparum (PfRBC), with uninfected 
erythrocytes (uRBC), or with phytohemagglutinin (PHA) 
as a positive control are shown before immunization 
(day I-1) and before malaria challenge (day C-1). Dashed 
lines represent the proportion of positive cells in un-
stimulated wells (culture medium only). The geomet-
ric mean fluorescence intensity of cells producing 
IFN-γ (Panel D), TNF-α (Panel E), and interleukin-2 
(Panel F) that were isolated from vaccinees on day C-1 
is shown after stimulation in vitro with infected eryth-
rocytes. Cells are grouped according to their positivity 
or negativity for each of the other two cytokines. In 
Panels G, H, and I, the proportion of lymphocytes that 
produced IFN-γ and interleukin-2 in response to in-
fected erythrocytes are shown on day I-1 and day C-1 
for lymphocyte phenotypes, including naive T cells 
(CD3+CD45RO−), memory T cells (CD3+CD45RO+), 
and non-T lymphocytes (CD3−CD45RO−) (Panel G); for 
T-cell phenotypes, including helper T cells (CD4+CD8−), 
cytotoxic T cells (CD4−CD8+), and other lymphocytes 
(CD4−CD8−) (Panel H); and for memory phenotypes, 
including naive T cells (CD62L+CD45RO−), central 
memory T cells (CD62L+CD45RO+), effector memory 
T cells (CD62L−CD45RO+), and other lymphocytes 
(CD62L−CD45RO−) (Panel I). The proportions of lym-
phocytes that produced IFN-γ and interleukin-2 after 
stimulation with uninfected erythrocytes were below 
0.005% (not shown). All P values are for the compari-
son between the vaccine group and the control group 
and were calculated with the use of the Mann–Whitney 
test. The T bars represent standard errors.
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In the field, in contrast, patent parasitemia 
typically develops before patients seek treatment. 
In such patients, acute blood-stage infection may 
suppress the induction of protective pre-erythro-
cytic immunity, as has been shown in rodent 
models.27 Indeed, parasitemic episodes or attacks 
of febrile malaria in Kenyan children are prospec-
tively associated with a poorer induction and more 
rapid attrition of cellular ex vivo and memory re-
sponses to a pre-erythrocytic P. falciparum antigen.28 
Thus, patent parasitemia and probably chronic 
subpatent parasitemia, which occur regularly in 
children in endemic areas, appear to induce in-
hibitory mechanisms that delay the generation of 
protective antiparasite immunity. Meta-analysis of 
studies of intermittent preventive therapy in in-
fants has decreased the concern about a rebound 
effect of prophylaxis and in some cases even in-
dicates sustained protection after discontinuation 
of prophylaxis,29 thus further indicating that the 
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acquisition and maintenance of protective immu-
nity do not depend on chronic blood-stage ex-
posure.
Thus, the salient feature of our approach 
seems to be the exposure of the immune system 
to a greater array of pre-erythrocytic and intra-
erythrocytic antigens, while restricting the devel-
opment of symptomatic and potentially immuno-
suppressive parasitemia.30 Since NF54 is known 
to be a chloroquine-sensitive strain in vitro,31 we 
cannot formally exclude a synergistic effect of 
residual subtherapeutic chloroquine levels on im-
munologic parasite clearance. However, chloro-
quine levels before the malaria challenge ap-
proached or fell below the limit of detection and 
had no measureable parasiticidal effect in control 
subjects. Of more importance, the longevity of 
immunologic responses, both naturally acquired 
and vaccine-induced, remains a critical issue in 
malaria, and follow-up studies are planned to ad-
dress this issue.
In this model, we have identified responses of 
pluripotent effector memory T cells as being as-
sociated with protection. In one study,32 undefined 
subgroups of lymphocytes with the same cytokine 
profile were associated with the induction and 
maintenance of antigen-specific T-cell memory in 
subjects who were immunized with pre-erythro-
cytic candidate malaria vaccines, but associations 
with protection were not explored. However, the 
potent effector function of pluripotent cells, as 
suggested by their high cytokine content, has been 
noted in other investigations that showed their 
protective role in other infectious diseases.33,34 
Further detailed investigations will be necessary 
to determine the longevity of this immunologic 
response, its association with central memory-type 
T-cell activity, and its ability to serve as a true 
correlate of protection.
Since the magnitude of the first wave of para-
sitemia is thought to directly reflect the burden 
of erupting mature liver schizonts, the stepwise 
decrease of such organisms after each subsequent 
immunizing infection and the absence of PCR-
detectable parasitemia after the malaria challenge 
would suggest that the protection in our model 
was primarily due to pre-erythrocytic immunity. 
However, a component of blood-stage immunity 
(i.e., the inhibition of erythrocyte invasion and 
maturation of minute liver-derived merozoite in-
ocula that cannot be detected on PCR) is also pos-
sible. Indeed, we found that cellular responses to 
asexual blood-stage parasites before challenge 
were a discriminative marker of exposure and 
protection in our subjects, and similar immune 
responses may have contributed to protection in 
the rodent model.12 However, many of the best-
studied P. falciparum antigens conferring protective 
immunity are shared among sporozoite, liver-
stage, and blood-stage parasites.35,36 Thus, it is 
plausible that our findings represent the response 
to a broad antigenic repertoire that transcends 
parasitic developmental stages,37 making a divi-
sion between pre-erythrocytic immunity and in-
traerythrocytic immunity inappropriate. At pres-
ent, the stage specificity of the protective immune 
response must remain formally unresolved, al-
though one way to further address this issue in 
future studies would be a blood-stage challenge.
Although the methods described here do not 
represent a widely implementable vaccine strat-
egy, the induction of sterile protection against a 
homologous malaria challenge suggests that the 
concept of a whole-parasite malaria vaccine war-
rants further consideration. In addition, this model 
allows the nature of protective immune responses 
against malaria, both stage-specific and antigen-
specific, to be further investigated.
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